(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
1.37% $ 103.19
@ $92.30
Выпущен: 14 февр. 2024 @ 17:40
Доходность: 11.80%
Предыдущий сигнал: февр. 13 - 17:30
Предыдущий сигнал:
Доходность: 0.53 %
Live Chart Being Loaded With Signals
Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally...
Stats | |
---|---|
Объем за сегодня | 18 627.00 |
Средний объем | 43 153.00 |
Рыночная капитализация | 556.61M |
EPS | $0 ( 2024-02-05 ) |
Дата следующего отчета о доходах | ( $2.33 ) 2024-05-24 |
Last Dividend | $0.160 ( 2023-11-29 ) |
Next Dividend | $0 ( N/A ) |
P/E | 607.00 |
ATR14 | $0.497 (0.48%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-02 | Sullivan John James | Sell | 450 | Non Qualified Stock Option |
2024-04-02 | Sakys John | Sell | 2 500 | Non Qualified Stock Option |
2024-04-02 | Owens Gary M | Sell | 5 000 | Non Qualified Stock Options |
2024-04-02 | Archbold Brian David | Sell | 420 | Non Qualified Stock Option |
2024-01-08 | Archbold Brian David | Sell | 290 | Non Qualified Stock Option |
INSIDER POWER |
---|
12.67 |
Last 100 transactions |
Buy: 73 301 | Sell: 52 584 |
Объем Корреляция
Mesa Laboratories Inc Корреляция
10 Самые положительные корреляции |
---|
10 Самые отрицательные корреляции |
---|
Вы знали?
Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).
Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.
Mesa Laboratories Inc Корреляция - Валюта/Сырье
Mesa Laboratories Inc Финансовые показатели
Annual | 2023 |
Выручка: | $219.08M |
Валовая прибыль: | $133.69M (61.02 %) |
EPS: | $0.170 |
FY | 2023 |
Выручка: | $219.08M |
Валовая прибыль: | $133.69M (61.02 %) |
EPS: | $0.170 |
FY | 2022 |
Выручка: | $184.34M |
Валовая прибыль: | $109.09M (59.18 %) |
EPS: | $0.360 |
FY | 2021 |
Выручка: | $133.94M |
Валовая прибыль: | $87.01M (64.97 %) |
EPS: | $0.660 |
Financial Reports:
No articles found.
Mesa Laboratories Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.160 (N/A) |
$0.160 (N/A) |
$0.160 (N/A) |
$0.160 (N/A) |
$0.160 (N/A) |
$0.160 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.200 | 2003-11-26 |
Last Dividend | $0.160 | 2023-11-29 |
Next Dividend | $0 | N/A |
Payout Date | 2023-12-15 | |
Next Payout Date | N/A | |
# dividends | 81 | -- |
Total Paid Out | $11.06 | -- |
Avg. Dividend % Per Year | 0.19% | -- |
Score | 4.41 | -- |
Div. Sustainability Score | 7.61 | |
Div.Growth Potential Score | 5.87 | |
Div. Directional Score | 6.74 | -- |
Year | Amount | Yield |
---|---|---|
2003 | $0.200 | 3.07% |
2004 | $0.410 | 4.07% |
2005 | $0.500 | 3.85% |
2006 | $0.390 | 2.60% |
2007 | $0.340 | 1.80% |
2008 | $0.400 | 1.54% |
2009 | $0.410 | 2.27% |
2010 | $0.450 | 1.70% |
2011 | $0.490 | 1.63% |
2012 | $0.530 | 1.29% |
2013 | $0.570 | 1.08% |
2014 | $0.610 | 0.79% |
2015 | $0.640 | 0.80% |
2016 | $0.640 | 0.64% |
2017 | $0.640 | 0.52% |
2018 | $0.640 | 0.51% |
2019 | $0.640 | 0.31% |
2020 | $0.640 | 0.26% |
2021 | $0.640 | 0.23% |
2022 | $0.640 | 0.20% |
2023 | $0.640 | 0.37% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.00445 | 1.500 | 9.91 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.00128 | 1.200 | 9.96 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.00241 | 1.500 | -1.084 | -1.626 | [0.1 - 1] |
payoutRatioTTM | 3.63 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 2.68 | 0.800 | 1.606 | 1.285 | [1 - 3] |
quickRatioTTM | 1.503 | 0.800 | 5.87 | 4.69 | [0.8 - 2.5] |
cashRatioTTM | 0.639 | 1.500 | 7.56 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.318 | -1.500 | 4.70 | -7.04 | [0 - 0.6] |
interestCoverageTTM | -2.03 | 1.000 | -1.862 | -1.862 | [3 - 30] |
operatingCashFlowPerShareTTM | 8.12 | 2.00 | 7.29 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 7.55 | 2.00 | 6.23 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.586 | -1.500 | 7.66 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.610 | 1.000 | 3.16 | 3.16 | [0.2 - 0.8] |
operatingProfitMarginTTM | -0.0438 | 1.000 | -2.88 | -2.88 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.185 | 1.000 | -0.0812 | -0.0812 | [0.2 - 2] |
assetTurnoverTTM | 0.287 | 0.800 | -1.420 | -1.136 | [0.5 - 2] |
Total Score | 7.61 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 587.03 | 1.000 | 10.00 | 0 | [1 - 100] |
returnOnEquityTTM | 0.00241 | 2.50 | -0.697 | -1.626 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 7.55 | 2.00 | 7.48 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.620 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 8.12 | 2.00 | 7.29 | 10.00 | [0 - 30] |
payoutRatioTTM | 3.63 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | 1.693 | 1.500 | 2.05 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.206 | 1.000 | 7.36 | 0 | [0.1 - 0.5] |
Total Score | 5.87 |
Mesa Laboratories Inc
Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in the United States, Europe, the Asia Pacific, and internationally. The company's Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. Its Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enables to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The company's Calibration Solutions segment designs, manufactures, and markets quality control and calibration products to measure or calibrate temperature, pressure, pH, humidity, and other such parameters used for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory and healthcare environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. Its Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in several therapeutic areas, such as newborn screenings, pharmacogenetics, and oncology. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.
О Торговые сигналы
Данные торговые сигналы, представленные на этой странице, помогают определить, когда следует ПОКУПАТЬ или ПРОДАВАТЬ NA. Сигналы имеют задержку более 1 минуты. Пожалуйста, примите во внимание, что существует вероятность ошибки или неточностей в силу различных микро и макро факторов влияющих на фондовые рынки.
Данные тор“о”ые сигна“ы не являются определен“ыми, и getagraph.com не несет ответственности за какие-либо действия, предпринятые в от“ошении этих сигналов, как описано в Terms of Use. Сигналы основаны на широком спектре индикаторов технического анализа